Bausch Health sells off Amoun for $740M; Achilles de­buts on Nas­daq with $175.5M IPO

Look­ing to pay down debt ahead of the big Bausch + Lomb spin­off, Bausch Health CEO Joseph Pa­pa has struck a deal to sell one of its units in Egypt for $740 mil­lion.

Abu Dhabi-based hold­ing com­pa­ny ADB is hand­ing over the cash for Amoun Phar­ma­ceu­ti­cal, which makes and mar­kets brand­ed gener­ics and an­i­mal health prod­ucts, will be the new own­er.

“The sale of Amoun marks sig­nif­i­cant progress in our ef­forts to re­duce over­all Bausch Health debt as we con­tin­ue to pur­sue all op­por­tu­ni­ties to dri­ve val­ue for our share­hold­ers, in­clud­ing prepar­ing for the spin­off of Bausch + Lomb,” said Joseph Pa­pa, chair­man and CEO, Bausch Health.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER